- DJO to Commercialize Exos' Next Generation Musculoskeletal Stabilization System -
SAN DIEGO, CA, - September 28, 2011 - DJO Global, Inc. (“DJO” or the “Company”), a leading global provider of medical device solutions for musculoskeletal health, vascular health and pain management, today announced that it has signed an exclusive distribution agreement with Exos Corporation, providing DJO with exclusive rights to sell Exos’ broad range of upper extremity products that incorporate Exos’ thermoformable polymer technology in North and South America. Terms of the distribution agreement were not disclosed. The agreement commences October 1, 2011.
Based in Arden Hills, MN, Exos Corporation is a medical device company focused on a revolutionary thermoformable external musculoskeletal stabilization system. The company has filed several U.S. patents for the application, materials and construction of its products and is continuously adding to its intellectual property portfolio.
Exos is the only thermoformable bracing system, offering a waterproof, removable, adjustable and reformable solution for the treatment of fractures and other injuries requiring stabilization. This innovative technology has the opportunity to dramatically change clinical practices for external musculoskeletal support and stabilization.
“It has always been DJO’s passion to identify innovative solutions to improve patient outcomes while controlling overall healthcare costs,” said Mike Mogul, president and chief executive officer of DJO Global. “Exos’ unique technology will enable DJO to market their next generation of upper extremity bracing and supports products now, while providing us with an impressive array of future opportunities.”
About Exos
Exos Corporation is a Minnesota medical device company that was incorporated in August, 2007. The company was created to develop and commercialize the next generation of thermoformable external musculoskeletal stabilization systems. It has evolved and grown as a collaborative venture between individuals with expertise in medical product design, development, clinical evaluations, business and marketing strategy development. As a result of this collaboration, the company has filed several U.S. patents for the application, materials and construction of its products and is continuously adding to its intellectual property portfolio. All involved have a shared goal of creating an exciting new technology that will save clinicians time, enhance patient satisfaction, and ultimately, improve clinical outcomes.
About DJO Global
DJO Global is a leading global developer, manufacturer and distributor of high-quality medical devices and services that provide solutions for musculoskeletal health, vascular health and pain management. The Company’s products address the continuum of patient care from injury prevention to rehabilitation after surgery, injury or from degenerative disease, enabling people to regain or maintain their natural motion. Its products are used by orthopedic specialists, spine surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers and other healthcare professionals. In addition, many of the Company’s medical devices and related accessories are used by athletes and patients for injury prevention and at-home physical therapy treatment. The Company’s product lines include rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management and physical therapy products. The Company’s surgical division offers a comprehensive suite of reconstructive joint products for the hip, knee and shoulder. DJO Global’s products are marketed under a portfolio of brands including Aircast®, Chattanooga, CMF™, Compex®, DonJoy®, Empi®, ProCare®, DJO® Surgical and Dr. Comfort®. For additional information on the Company, please visit www.DJOglobal.com.
DJO Investor/Media Contact:
DJO Global, Inc.
Mark Francois, Director of Investor Relations
(760) 734-4766
